(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
Dr. Charles Bishop, CEO of OPKO Health Renal Division, to discuss the FDA’s approval of Rayaldee and the health issues surrounding chronic kidney disease

<p>(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
Dr. Charles Bishop, CEO of OPKO Health Renal Division, to discuss the FDA’s approval of Rayaldee and the health issues surrounding chronic kidney disease</p>

Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

<p>Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.</p>

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze markets, companies and industries.

Bloomberg Intelligence

OPKO’s Bishop on FDA Approval Of Its Kidney Disease Drug(Audio)

OPKO's Bishop on FDA Approval Of Its Kidney Disease Drug(Audio)

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/62359151-a57c-42f4-93c3-ae3c009d6437/transcript

Advertisement